People: Anthera Pharmaceuticals Inc (ANTH.W)
ANTH.W on CBOE When Trading NASDAQ Global Select Market
0.59USD
30 May 2013
0.59USD
30 May 2013
Price Change (% chg)
$0.04 (+6.90%)
$0.04 (+6.90%)
Prev Close
$0.55
$0.55
Open
$0.59
$0.59
Day's High
$0.59
$0.59
Day's Low
$0.59
$0.59
Volume
200
200
Avg. Vol
6
6
52-wk High
$3.08
$3.08
52-wk Low
$0.51
$0.51
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Christopher Henney |
72 | 2008 | Independent Chairman of the Board |
Paul Truex |
43 | 2004 | President, Chief Executive Officer, Director |
Christopher Lowe |
44 | 2011 | Chief Financial Officer, Chief Business Officer |
May Liu |
38 | 2013 | Senior Vice President - Finance and Administration, Principal Accounting Officer |
Debra Odink |
48 | 2011 | Senior Vice President, Chief Technology Officer |
Colin Hislop |
54 | 2010 | Senior Vice President, Chief Medical Officer |
Sanford Zweifach |
50 | 2013 | Director |
Bogdan Dziurzynski |
64 | 2012 | Independent Director |
James Healy |
2006 | Independent Director | |
Daniel Spiegelman |
54 | 2010 | Independent Director |
David Thompson |
64 | 2005 | Independent Director |
Biographies
| Name | Description |
|---|---|
Christopher Henney |
Dr. Christopher S. Henney, Ph.D., serves as Independent Chairman of the Board of Directors of Anthera Pharmaceuticals Inc., since August 2008. He has been a Member of the Board of Directors since April 2005. Dr. Henney served as Chairman and Chief Executive Officer of Dendreon Corporation, a biotechnology company he co-founded, from 1995 until his retirement in July 2004. Dr. Henney was previously a founder of Immunex Corp. and Icos Corp. Dr. Henney holds a B.Sc. with honors in medical biochemistry, a Ph.D. in experimental pathology and a D.Sc. for contributions to the field of immunology, all from the University of Birmingham, England. Dr. Henney served as a director of AVI BioPharma Inc. from March 2009 until June 2010 and is currently the Chairman and a director of Oncothyreon, Inc. and is vice-chairman and a director of Cyclacel Pharmaceuticals, Inc. |
Paul Truex |
Mr. Paul F. Truex serves as President, Chief Executive Officer, Director of Anthera Pharmaceuticals Inc. Mr. Truex has served as the company's President and Chief Executive Officer since the company's inception in September 2004 and as a member of board of directors since November 2004. Prior to founding Anthera, Mr. Truex served as a Director, President and Chief Executive Officer of Peninsula Pharmaceuticals, Inc., a biopharmaceutical company, from the commencement of its operations in October 2001. Prior to Peninsula, Mr. Truex was Vice President of Commercial Development for Vicuron, Inc. from April 2000 to September 2001. From July 1997 to April 2000, Mr. Truex held various positions at Eli Lilly and Company. Mr. Truex holds an M.B.A. in marketing and finance from Indiana University and a B.A. in economics from the University of Waterloo. Mr. Truex is a director of Trius Therapeutics, Inc. and Eiger Biopharmaceuticals, Inc. Mr. Truex holds an M.B.A. in marketing and finance from Indiana University and a B.A. in economics from the University of Waterloo. Mr. Truex is a director of Trius Therapeutics, Inc. and Eiger Biopharmaceuticals, Inc. |
Christopher Lowe |
Mr. Christopher P. Lowe has resigned as Chief Financial Officer, Chief Business Officer of Anthera Pharmaceuticals Inc., effective June 30, 2013. Prior to that time and since November 2007, he served as Chief Financial Officer and Vice President of Administration. Beginning in September 2005 and up until he joined the company, Mr. Lowe served as Vice President of Finance & Administration and, beginning in January 2006, as Chief Financial Officer of Asthmatx, Inc., a medical technology company. Previously, Mr. Lowe was with Peninsula Pharmaceuticals, Inc., as Corporate Controller from June 2004 to October 2004 and Chief Accounting Officer from October 2004 until June 2005. Mr. Lowe holds a B.S. in business administration from California Polytechnic State University, San Luis Obispo and an M.B.A. from Saint Mary’s University, Texas. Mr. Lowe is a director of Hansen Medical Corporation, a medical device company. |
May Liu |
Ms. May Liu has been appointed as Senior Vice President - Finance and Administration, Principal Accounting Officer of Anthera Pharmaceuticals, Inc., effective June 12, 2013. Ms. Liu has served as the Company's Vice President, Finance since January 2011. Prior to that, she served as Anthera's Corporate Controller since October 2007. Ms. Liu joined the Company as Director of Finance in April 2007. Prior to that, Ms. Liu served as SEC Reporting and Technical Accounting Manager at Renovis, Inc., a clinical-stage pharmaceutical company, from October 2005 to March 2007. Ms. Liu has been a Certified Public Accountant since 2007 and was a part of the audit and assurance practice of Ernst & Young, LLP. from 2000 to 2005, focusing primarily in the life science industry. Ms. Liu holds a B.S. in business administration with a concentration in accounting from San Francisco State University. |
Debra Odink |
Dr. Debra Odink, Ph.D., serves as Senior Vice President, Chief Technology Officer of Anthera Pharmaceuticals Inc. Prior to that, she served as Senior Vice President of Pharmaceutical Research and Development since June 2010, and as Vice President of Pharmaceutical Research and Development since December 2005. From September 2002 until July 2005, Dr. Odink served as Vice President of Pharmaceutical Chemistry and Product Development at Peninsula Pharmaceuticals, Inc., a biopharmaceutical company, where she was responsible for manufacturing and product development strategies for assets licensed to Peninsula. Dr. Odink holds a B.S. in chemistry from California State University, Stanislaus and a Ph.D. in inorganic chemistry from the University of California at Davis. |
Colin Hislop |
Dr. Colin Hislop, M.D., serves as Senior Vice President, Chief Medical Officer of Anthera Pharmaceuticals Inc., since June 2010. Prior to that, he served as the company's Senior Vice President of Cardiovascular Products since November 2005 and also served as a consultant to the company from July 2005 through November 2005. From October 2004 until June 2005, Dr. Hislop was Vice President, Clinical Development for Peninsula Pharmaceuticals, Inc. where he oversaw three global development programs for Peninsula’s anti-infective product portfolio. From September 2001 until September 2004, Dr. Hislop served as Vice President of Clinical Development at CV Therapeutics, Inc., a biopharmaceutical company. Dr. Hislop holds a B.Sc. in medical biochemistry from the University of Surrey, and a degree in medicine from the University of London. |
Sanford Zweifach |
Mr. Sanford S. Zweifach has been appointed as Director of Anthera Pharmaceuticals, Inc., effective March 25, 2013. Mr. Zweifach is a senior executive with over 20 years in the life sciences industry. He has experience in the areas of corporate partnering, business development, operational and financial experience, private and public investing and capital raising. From 2005 until 2010, Mr. Zweifach was a Managing Director at Reedland Capital Partners, a boutique investment bank, where he headed its life sciences merger and acquisition, and advisory efforts, bringing with him 15 years of proven experience in investment banking, investing, business development, merger and acquisition, and management. Prior to joining Reedland, Mr. Zweifach was Chief Executive Officer of Pathways Diagnostics Corp, a biomarker development company. Previously, from 1997 to 2003, Mr. Zweifach was Chief Financial Officer and Managing Director of Bay City Capital, LLC, a merchant bank specializing in the biotech and life science industry, where he was responsible for oversight of the firm’s finance department as well as President of the firm’s merger and acquisition, and financing division. From 1995 to 1998, Mr. Zweifach was President and Chief Financial Officer of Epoch Biosciences Corporation, which was acquired by Nanogen in 2004. Previously, Mr. Zweifach was a Certified Public Accountant for Coopers & Lybrand and held various investment banking positions focusing in the biotechnology industry. Mr. Zweifach received his B.A. in Biology from University of California, San Diego and holds an M.S. in Human Physiology from University of California, Davis. |
Bogdan Dziurzynski |
Dr. Bogdan Dziurzynski, D.P.A. serves as an Independent Director of Anthera Pharmaceuticals Inc., since March 1, 2012. Dr. Dziurzynski has a history of experience. He currently serves as a strategic regulatory management consultant to the biotechnology industry and serves on the Board of Directors of Dendreon Corporation and the Biologics Consulting Group, Inc. Dr. Dziurzynski is a fellow and past chairman of the board and a past president of the Regulatory Affairs Professional Society. He also serves as an advisory board member of Integrated Biotherapeutics, Inc. From 1994 to 2001, Dr. Dziurzynski was the Senior Vice President of Regulatory Affairs and Quality Assurance for MedImmune, Inc., a biotechnology company. From 1988 to 1994, Dr. Dziurzynski was Vice President of Regulatory Affairs and Quality Assurance for Immunex Corporation, a biotechnology company. He has a B.A. in Psychology from Rutgers University, an M.B.A. from Seattle University and a Doctorate in Public Administration from the University of Southern California. |
James Healy |
Dr. James I. Healy, M.D., Ph.D., serves as an Independent Director of Anthera Pharmaceuticals Inc., Dr. Healy is a Managing Member of Sofinnova Management VI, LLC, the general partner of Sofinnova Venture Partners VI, L.P., a fund managed by Sofinnova Ventures, Inc., a venture capital firm, a position he has held since June 2000. Prior to Sofinnova, Dr. Healy began his private equity career at Sanderling Ventures, and has been an early investor and board member of numerous biopharmaceutical companies. Dr. Healy holds a B.A. in molecular biology and a B.A. in Scandinavian studies from the University of California at Berkeley, an M.D. from Stanford University School of Medicine and a Ph.D. in immunology from Stanford University. Dr. Healy is a director of InterMune, Inc. and Amarin Corporation plc, both biopharmaceutical companies. |
Daniel Spiegelman |
Mr. Daniel K. Spiegelman serves as an Independent Director of Anthera Pharmaceuticals Inc., since February 2010. Currently, Mr. Spiegelman provides management and financial consulting services to biotechnology companies. From January 1998 to May 2009, Mr. Spiegelman served as Senior Vice President and Chief Financial Officer of CV Therapeutics, Inc., a biopharmaceutical company that was acquired by Gilead Sciences, Inc. in April 2009. From July 1991 to January 1998, Mr. Spiegelman served at Genentech, Inc., most recently as Treasurer. Mr. Spiegelman also serves on the board of directors of Affymax, Inc., Cyclacel Pharmaceuticals, Inc., Omeros Corporation and Oncothyreon, Inc., all of which are publicly-traded biopharmaceutical companies. Mr. Spiegelman also previously served on the board of directors of Xcyte Therapies, Inc. from 2003 through 2006, a publicly-traded company, until Cyclacel acquired Xcyte via reverse merger in 2006. Mr. Spiegelman holds a B.A. in economics from Stanford University and an M.B.A. from the Stanford Graduate School of Business. |
David Thompson |
Mr. David E. Thompson serves as an Independent Director of Anthera Pharmaceuticals Inc., since November 2005. Mr. Thompson served as Vice President of Corporate Strategy Business Development for Eli Lilly and Company from January 2001 until his retirement in July 2005. Thereafter, he was a partner at VantagePoint Venture Partners from 2006 through 2008. Mr. Thompson holds a B.S. and an M.B.A. from Michigan State University. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Christopher Henney |
-- |
Paul Truex |
1,486,080 |
Christopher Lowe |
943,092 |
May Liu |
-- |
Debra Odink |
622,372 |
Colin Hislop |
936,716 |
Sanford Zweifach |
-- |
Bogdan Dziurzynski |
-- |
James Healy |
-- |
Daniel Spiegelman |
-- |
David Thompson |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Christopher Henney |
0 | 0 |
Paul Truex |
80,000 | 446,500 |
Christopher Lowe |
30,000 | 184,401 |
May Liu |
0 | 0 |
Debra Odink |
3,311 | 12,582 |
Colin Hislop |
40,000 | 295,298 |
Sanford Zweifach |
0 | 0 |
Bogdan Dziurzynski |
0 | 0 |
James Healy |
0 | 0 |
Daniel Spiegelman |
0 | 0 |
David Thompson |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
DZIURZYNSKI BOGDAN |
10,000 | $0.59 |
TRUEX PAUL F |
100,000 | $0.00 |
ODINK DEBRA A |
49,519 | $0.00 |
TRUEX PAUL F |
135,644 | $0.00 |
LOWE CHRISTOPHER P |
67,579 | $0.00 |
HISLOP COLIN |
59,132 | $0.00 |
ORBIMED ADVISORS L L C |
5,700,000 | $0.66 |
ORBIMED ADVISORS L L C |
1,762,000 | $0.65 |
ODINK DEBRA A |
4,009 | $0.00 |
ODINK DEBRA A |
4,009 | $0.00 |
TRUEX PAUL F |
66,412 | $0.00 |
TRUEX PAUL F |
66,412 | $0.00 |
HISLOP COLIN |
4,560 | $0.69 |
TRUEX PAUL F |
17,454 | $0.69 |
KILFOIL GEORGINA H |
2,410 | $0.69 |
ODINK DEBRA A |
3,409 | $0.69 |
LOWE CHRISTOPHER P |
8,660 | $0.69 |
ODINK DEBRA A |
1,838 | $0.69 |
KILFOIL GEORGINA H |
2,068 | $0.69 |
HENNEY CHRISTOPHER S |
100,000 | $0.75 |
ORBIMED ADVISORS L L C |
1,283,300 | $0.73 |
HENNEY CHRISTOPHER S |
100,000 | $0.75 |
ORBIMED ADVISORS L L C |
1,306,700 | $2.40 |
ORBIMED ADVISORS L L C |
125,000 | $2.87 |
ORBIMED ADVISORS L L C |
116,800 | $2.90 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
